Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 8, 2025
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
GlobeNewswire
·
April 8, 2025
EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically debilitating Preeclampsia, a serious obstetric complication, is a leading cause of near-term morbidity and mortality for mothers and …
Microbix Provides Business Updates
GlobeNewswire
·
April 8, 2025
MISSISSAUGA, Ontario, April 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator, manufacturer, and exporter, provides an update on U.S. and reciprocal tariff outcomes as …
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
GlobeNewswire
·
April 8, 2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the …
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
GlobeNewswire
·
April 8, 2025
POMPANO BEACH, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that …
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
GlobeNewswire
·
April 8, 2025
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of …
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
GlobeNewswire
·
April 8, 2025
VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce …
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
GlobeNewswire
·
April 8, 2025
FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all manufactured batches PAS approval follows recent FDA approval of new formulation, EGRIFTA WR™ MONTREAL, April 08, 2025 (GLOBE NEWSWIRE) -- …
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
GlobeNewswire
·
April 8, 2025
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in …
Routine medical appointments and cancer screenings head in the wrong direction
GlobeNewswire
·
April 8, 2025
ALEXANDRIA, Va., April 08, 2025 (GLOBE NEWSWIRE) -- When was the last time you saw your doctor? There’s been a change in how often U.S. adults are going to routine medical appointments and cancer screenings, and according to the Prevent Cancer Foundation’s …
Tilray Brands Reports Q3 Fiscal 2025 Financial Results
GlobeNewswire
·
April 8, 2025
Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. …
Theratechnologies reçoit l’approbation de la FDA pour le supplément d’approbation préalable [PAS] relatif à sa demande d’un supplément à la licence de produit biologique (sBLA) pour EGRIFTA SV(MD)
GlobeNewswire
·
April 8, 2025
L’approbation de la FDA permet une distribution sans restriction d’EGRIFTA SVMD, levant ainsi l'incertitude concernant tous les lots fabriqués L’approbation du PAS fait suite à l’approbation récente de la nouvelle formulation, EGRIFTA WRMC MONTRÉAL, 08 avr …
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
GlobeNewswire
·
April 8, 2025
Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Telix Announces Cardinal Health for Gozellix Commercial Distribution
GlobeNewswire
·
April 8, 2025
MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its …
Teladoc Health Introduces Next Generation Cardiometabolic Health Program
GlobeNewswire
·
April 8, 2025
PURCHASE, NY, April 08, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today introduced its next generation Cardiometabolic Health Program to improve population health and prevent the progression of diabetes, …
Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development
GlobeNewswire
·
April 8, 2025
Steen Lisby, M.D., D.MSc. joins as Chief Medical Officer Jesper Valbjørn, M.Sc. joins as Senior Vice President CMC Ongoing team expansion at Myricx Bio's new facilities in London’s Canary Wharf biotech hub following 2024 £90 million ($114 million) series A …
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
GlobeNewswire
·
April 8, 2025
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the …
Phonak Audéo Sphere Infinio wins Gold Edison Award for innovation in consumer solutions
GlobeNewswire
·
April 8, 2025
STÄFA, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Phonak, a global leader in innovative hearing solutions, is proud to announce that the Phonak Audéo Sphere Infinio has been awarded the prestigious Gold Edison Award in the category of Consumer …
Nyxoah Provides Update on FDA Approvable Letter for Genio System
GlobeNewswire
·
April 8, 2025
Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: …
Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système Genio
GlobeNewswire
·
April 8, 2025
Nyxoah Présente une Mise à Jour Concernant la Lettre d'Approuvabilité de la FDA pour le Système Genio Prévoit de satisfaire aux exigences finales de la FDA pour obtenir l'approbation PMA complète au cours du deuxième trimestre Mont-Saint-Guibert, Belgique …
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
GlobeNewswire
·
April 8, 2025
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo’s durable …